GSK Receives FDA Accelerated Approval for Nelkarmi in ALK-Positive Non-Small Cell Lung Cancer
Trendline

GSK Receives FDA Accelerated Approval for Nelkarmi in ALK-Positive Non-Small Cell Lung Cancer

What's Happening? The U.S. Food and Drug Administration (FDA) has granted accelerated approval to GSK's ALK inhibitor, Nelkarmi (neladalkib), for the treatment of advanced-stage ALK-positive non-small cell lung cancer (NSCLC). This approval is specifically for patients who have previously undergone
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.